4D Pharma reports Phase I/II data for Keytruda-based combination

The trial involves patients with melanoma, renal cell carcinoma, NSCLC and bladder cancer. Credit: Nephron.



  • 4D pharma reports Phase I/II data for Keytruda-based combination